Erratum to: Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma

[1]  A. Ferrari,et al.  Thymoma and thymic carcinoma in children and adolescents: a report from the European Cooperative Study Group for Pediatric Rare Tumors (EXPeRT). , 2015, European journal of cancer.

[2]  H. Ohmatsu,et al.  Docetaxel for platinum-refractory advanced thymic carcinoma. , 2015, Japanese journal of clinical oncology.

[3]  H. Wakelee,et al.  A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies. , 2015, Lung cancer.

[4]  Y. Hosomi,et al.  Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma , 2015, BMC Cancer.

[5]  K. Ramchandran,et al.  Phase II trial of single agent amrubicin (A) in patients (pts) with previously treated advanced thymic malignancies (TM). , 2015 .

[6]  Y. Ohe,et al.  Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma. , 2015, Lung cancer.

[7]  Y. Hosomi,et al.  Response to cytotoxic chemotherapy in patients previously treated with palliative-intent chemotherapy for advanced thymic carcinoma. , 2015, Clinical lung cancer.

[8]  R. West,et al.  Diffuse High Intensity PD–L1 Staining in Thymic Epithelial Tumors , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  P. Meltzer,et al.  Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. , 2015, The Lancet. Oncology.

[10]  M. Coleman,et al.  Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  Y. Hosomi,et al.  Key components of chemotherapy for thymic malignancies: a systematic review and pooled analysis for anthracycline-, carboplatin- or cisplatin-based chemotherapy , 2014, Journal of Cancer Research and Clinical Oncology.

[12]  A. Chella,et al.  Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Marino,et al.  Capecitabine plus gemcitabine in thymic epithelial tumors: final analysis of a Phase II trial. , 2014, Future oncology.

[14]  G. Giaccone,et al.  A phase II study of milciclib (PHA-848125AC) in patients (pts) with thymic carcinoma (TC). , 2014 .

[15]  P. Casali,et al.  Rare cancers: work in progress in Europe. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  N. Girard,et al.  胸腺恶性肿瘤化疗的相关定义和策略 , 2014, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

[17]  G. Giaccone,et al.  Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. , 2014, The Lancet. Oncology.

[18]  D. Ettinger,et al.  Thymomas and thymic carcinomas , 2013 .

[19]  G. Scagliotti,et al.  Messenger RNA and protein expression of thymidylate synthase and DNA repair genes in thymic tumors. , 2013, Lung cancer.

[20]  A. Marchetti,et al.  Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  N. Girard.  Chemotherapy and targeted agents for thymic malignancies , 2012, Expert review of anticancer therapy.

[22]  Yukiko Nakamura,et al.  Expression of thymidylate synthase, orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in thymic epithelial tumors. , 2011, Lung cancer.

[23]  G. Gatta,et al.  Rare cancers are not so rare: the rare cancer burden in Europe. , 2011, European journal of cancer.

[24]  G. Giaccone,et al.  Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Y. Hosomi,et al.  S-1 is an active anticancer agent for advanced thymic carcinoma. , 2010, Lung cancer.

[26]  E. Engels.  Epidemiology of Thymoma and Associated Malignancies , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[27]  A. Marx,et al.  Sunitinib in metastatic thymic carcinomas: Laboratory findings and initial clinical experience , 2010, British Journal of Cancer.

[28]  G. Giaccone,et al.  Imatinib Mesylate in Patients with WHO B3 Thymomas and Thymic Carcinomas , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[29]  T. Naito,et al.  S-1 treatment for chemorefractory thymic carcinoma. , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[30]  R. Nelson,et al.  A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma , 2008 .

[31]  A. Astudillo,et al.  Identifying the most suitable endogenous control for determining gene expression in hearts from organ donors , 2007, BMC Molecular Biology.

[32]  C. Yiannoutsos,et al.  A phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  W. Pao,et al.  Phase II study of gefitinib treatment in advanced thymic malignancies , 2005 .

[34]  F. Rea,et al.  Long-term survival and prognostic factors in thymic epithelial tumours. , 2004, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[35]  A. Marx,et al.  Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. , 2004, The New England journal of medicine.

[36]  K. Kondo,et al.  WHO histologic classification is a prognostic indicator in thymoma. , 2004, The Annals of thoracic surgery.

[37]  D. Ettinger,et al.  Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  D. Nadal,et al.  Quantitative cytokine gene expression in human tonsils at excision and during histoculture assessed by standardized and calibrated real-time PCR and novel data processing. , 2003, Journal of immunological methods.

[39]  C. Blanke,et al.  Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  K. Eguchi,et al.  A case of recurrent metastatic thymoma showing a marked response to paclitaxel monotherapy. , 2002, Japanese journal of clinical oncology.

[41]  H. Matsuda,et al.  The World Health Organization histologic classification system reflects the oncologic behavior of thymoma , 2002, Cancer.

[42]  Martin R. Johnson,et al.  Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  M. Highley,et al.  Treatment of invasive thymoma with single-agent ifosfamide. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  S. Groshen,et al.  High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[45]  K. Yeh,et al.  Thymic carcinoma with autoimmune syndrome: successful treatment with weekly infusional high-dose 5-fluorouracil and leucovorin. , 1997, Anticancer research.

[46]  G. Giaccone,et al.  Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  P. Danenberg.  Thymidylate synthetase - a target enzyme in cancer chemotherapy. , 1977, Biochimica et biophysica acta.

[48]  R. West,et al.  Pemetrexed in patients with thymic malignancies previously treated with chemotherapy. , 2015, Lung cancer.

[49]  K. Kubo,et al.  Successful S-1 monotherapy for chemorefractory thymic carcinoma. , 2011, Anticancer research.

[50]  Qiang Chen,et al.  Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report , 2009, Medical oncology.

[51]  W. Timens,et al.  Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy. , 2008, European journal of cancer.

[52]  G. Peters,et al.  Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5'-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes. , 1986, Cancer research.